๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

New bisphosphonates in the treatment of bone metastases

โœ Scribed by Steven D. Averbuch


Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
961 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Oral bisphosphonates : A review of clini
โœ Pierre P. Major; Allan Lipton; James Berenson; Gabriel Hortobagyi ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 88 KB ๐Ÿ‘ 2 views

## BACKGROUND. This study was conducted to review the efficacy and safety of oral bisphosphonates for the treatment of bone metastases in cancer patients. ## METHODS. Available published clinical studies of oral bisphosphonates in bone metastases from 1980 to the present were identified through a

Gallium nitrate for the treatment of bon
โœ Raymond P. Warrell Jr. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 157 KB ๐Ÿ‘ 2 views

ther studies have revealed that this drug has extremely potent effects on turnover of bone, and that low doses can be used to reduce bone resorption. Like the Developmental Chemotherapy Service, Departbisphosphonates, gallium nitrate has been studied in both malignant and in non-ment of Medicine, Me

Massive bone allografts in the treatment
โœ Salai, Moshe; Rahamimov, Nimrod; Pritch, Moshe; Rotstein, Zev; Horoszowski, Henr ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 125 KB ๐Ÿ‘ 2 views

Background and Objectives: Pathologic fractures due to disseminated metastases are common and often involve major long bones, where the metastasis is responsible for wide bone erosion that is equivalent to major bone loss. Stabilization of these fractures necessitates tumor excision and reconstructi

Effect of a newly developed bisphosphona
โœ Akira Sasaki; Kazuyuki Kitamura; Rafael E. Alcalde; Toshimitsu Tanaka; Atushi Su ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 288 KB ๐Ÿ‘ 2 views

YH529, [1-hydroxy-2-(imidazo [1,2-a] pyridin-3-yl) ethylidene]-bisphosphonic acid monohydrate, is a newly developed third-generation bisphosphonate with a potent inhibitory activity toward osteoclastic bone resorption. The primary cellular mechanism of osteolysis associated with metastatic cancer is